cytochrome P450 family 3 subfamily A member 43Genealiases: []
Q-omics provides the consensus-scored CYP3A43 profile across patient tissues and cancer cell-line models. CYP3A43 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CYP3A43 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, CYP3A43 RNA expression shows 14,007 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where CYP3A43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP3A43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP3A43 survival associations across molecular data types. CYP3A43 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP3A43 RNA expression–survival associations across cancer types. High CYP3A43 expression shows unfavorable associations in UVM, KICH and CESC, but favorable associations in BRCA, LIHC and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CYP3A43 RNA expression.
This table summarizes CYP3A43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP3A43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP3A43 shows lower tumor expression in LIHC, BRCA, CHOL, KIRP and PRAD and higher tumor expression in KIRC. The LIHC box plot shows higher CYP3A43 RNA expression in normal versus tumor tissue (log2 FC = −2.069, t-test p < 0.001).
This table shows molecular features associated with CYP3A43 in patient tissues and cancer cell lines. In patient samples, CYP3A43 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP3A43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
